Yayın:
Pharmacokinetics of tolfenamic acid after different administration routes in geese (Anser cygnoides)

dc.contributor.authorTurk, Erdinc
dc.contributor.authorTekeli, Ibrahim Ozan
dc.contributor.authorDurna Corum, Duygu
dc.contributor.authorCorum, Orhan
dc.contributor.authorSakin, Fatih
dc.contributor.authorUney, Kamil
dc.date.accessioned2026-01-04T15:07:20Z
dc.date.issued2021-02-18
dc.description.abstractAbstractThe pharmacokinetics and bioavailability of tolfenamic acid were determined in geese (Anser cygnoides) following intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral administrations at 2 mg/kg dose. In this study, eight healthy geese (3.5 ± 0.5 kg) were used. The study was performed in four periods according to a crossover design with a 15‐day washout period between two administrations. The plasma concentrations of tolfenamic acid were analyzed using HPLC‐UV, and pharmacokinetic parameters were calculated by noncompartmental analysis. The elimination half‐life was 1.73, 2.51, 2.34, and 2.31 hr for IV, IM, SC, and oral routes, respectively. The volume of distribution at steady state and total clearance after IV administration were 0.25 L/kg and 0.16 L hr−1 kg−1, respectively. The peak plasma concentrations of tolfenamic acid after IM, SC, and oral administrations were 4.89, 2.94, and 2.92 μg/ml at 0.25, 0.75, and 1 hr, respectively. The bioavailability was 87.91, 77.87, and 76.03% for the IM, SC, and oral routes, respectively. Tolfenamic acid, which exhibits the good bioavailability and plasma concentration following IM, SC, and oral administrations at 2 mg/kg dose, may be useful in the treatment of inflammatory disease conditions in geese.
dc.description.urihttps://doi.org/10.1111/jvp.12956
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/33598927
dc.description.urihttps://dx.doi.org/10.1111/jvp.12956
dc.identifier.doi10.1111/jvp.12956
dc.identifier.eissn1365-2885
dc.identifier.endpage387
dc.identifier.issn0140-7783
dc.identifier.openairedoi_dedup___::7ff079d48fcfaada9995dbf1b89aab22
dc.identifier.orcid0000-0003-1735-1774
dc.identifier.orcid0000-0002-6845-2279
dc.identifier.orcid0000-0003-1567-991x
dc.identifier.orcid0000-0003-3168-2510
dc.identifier.orcid0000-0001-5377-0322
dc.identifier.orcid0000-0002-8674-4873
dc.identifier.pubmed33598927
dc.identifier.scopus2-s2.0-85100911812
dc.identifier.startpage381
dc.identifier.urihttps://hdl.handle.net/20.500.12597/38610
dc.identifier.volume44
dc.identifier.wos000619017800001
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.rightsCLOSED
dc.subjectArea Under Curve
dc.subjectGeese
dc.subjectInjections, Intravenous
dc.subjectAnimals
dc.subjectBiological Availability
dc.subjectortho-Aminobenzoates
dc.subjectInjections, Intramuscular
dc.subjectHalf-Life
dc.titlePharmacokinetics of tolfenamic acid after different administration routes in geese (Anser cygnoides)
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Erdinc Turk","name":"Erdinc","surname":"Turk","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1735-1774"},"provenance":null}},{"fullName":"Ibrahim Ozan Tekeli","name":"Ibrahim Ozan","surname":"Tekeli","rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0002-6845-2279"},"provenance":null}},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":3,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Fatih Sakin","name":"Fatih","surname":"Sakin","rank":5,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0001-5377-0322"},"provenance":null}},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":6,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Geese"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Biological Availability"},"provenance":null},{"subject":{"scheme":"keyword","value":"ortho-Aminobenzoates"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intramuscular"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Pharmacokinetics of tolfenamic acid after different administration routes in geese (<i>Anser cygnoides</i>)","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>The pharmacokinetics and bioavailability of tolfenamic acid were determined in geese (<jats:italic>Anser cygnoides</jats:italic>) following intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral administrations at 2 mg/kg dose. In this study, eight healthy geese (3.5 ± 0.5 kg) were used. The study was performed in four periods according to a crossover design with a 15‐day washout period between two administrations. The plasma concentrations of tolfenamic acid were analyzed using HPLC‐UV, and pharmacokinetic parameters were calculated by noncompartmental analysis. The elimination half‐life was 1.73, 2.51, 2.34, and 2.31 hr for IV, IM, SC, and oral routes, respectively. The volume of distribution at steady state and total clearance after IV administration were 0.25 L/kg and 0.16 L hr<jats:sup>−1</jats:sup> kg<jats:sup>−1</jats:sup>, respectively. The peak plasma concentrations of tolfenamic acid after IM, SC, and oral administrations were 4.89, 2.94, and 2.92 μg/ml at 0.25, 0.75, and 1 hr, respectively. The bioavailability was 87.91, 77.87, and 76.03% for the IM, SC, and oral routes, respectively. Tolfenamic acid, which exhibits the good bioavailability and plasma concentration following IM, SC, and oral administrations at 2 mg/kg dose, may be useful in the treatment of inflammatory disease conditions in geese.</jats:p>"],"publicationDate":"2021-02-18","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_14cb","label":"CLOSED","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"387","iss":null,"sp":"381","vol":"44","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::7ff079d48fcfaada9995dbf1b89aab22","originalIds":["10.1111/jvp.12956","50|doiboost____|7ff079d48fcfaada9995dbf1b89aab22","33598927","3130368348"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12956"},{"scheme":"pmid","value":"33598927"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":20,"influence":3.3371652e-9,"popularity":1.7412479e-8,"impulse":17,"citationClass":"C4","influenceClass":"C4","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12956"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12956"],"publicationDate":"2021-02-18","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"33598927"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12956"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/33598927"],"publicationDate":"2021-11-24","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12956"},{"scheme":"mag_id","value":"3130368348"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12956"],"refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar